Identification of dysregulated microRNAs in triple-negative breast cancer (Review)

Yang,Fang; Zhang,Wenwen; Shen,Yan; Guan,Xiaoxiang

doi:10.3892/ijo.2015.2821

Identification of dysregulated microRNAs in triple-negative breast cancer (Review)

Authors:
- Fang Yang
- Wenwen Zhang
- Yan Shen
- Xiaoxiang Guan
View Affiliations

Affiliations: Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China
Published online on: January 8, 2015 https://doi.org/10.3892/ijo.2015.2821
Pages: 927-932

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple-negative breast cancer (TNBC) is defined by the absence of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). TNBC exhibits a more aggressive phenotype and a poorer clinical outcome compared to other breast cancer subgroups, accounting for 15-20% of total breast cancer cases. To date, the treatment strategies for TNBC are limited to surgery, chemotherapy and radiation, owing to the lack of effective therapeutic targets. Therefore, it is important to identify specific targets for TNBCs. MicroRNAs (miRNAs), a family of small non-coding RNAs regulating gene expression, are an emerging class of regulators of various biological processes, including cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and drug resistance. Actually, miRNAs may serve as a novel therapeutic target in TNBC, and here we review current correlated researches and provide our own profiling results for the miRNAs expressed in TNBC cell lines. The present study offers an additional insight into the potential miRNAs involved in the regulation of TNBC.

View Figures

View References

1	Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
2	Di Leva G and Croce CM: Roles of small RNAs in tumor formation. Trends Mol Med. 16:257–267. 2010. View Article : Google Scholar : PubMed/NCBI
3	Lowery AJ, Miller N, Devaney A, et al: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/ neu receptor status in breast cancer. Breast Cancer Res. 11:R272009. View Article : Google Scholar
4	Gasparini P, Cascione L, Fassan M, et al: microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 5:1174–1184. 2014.PubMed/NCBI
5	Buffa FM, Camps C, Winchester L, et al: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 71:5635–5645. 2011. View Article : Google Scholar : PubMed/NCBI
6	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cochrane DR, Cittelly DM, Howe EN, et al: MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 1:306–319. 2010. View Article : Google Scholar
8	Foekens JA, Sieuwerts AM, Smid M, et al: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA. 105:13021–13026. 2008. View Article : Google Scholar : PubMed/NCBI
9	Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S and Caplen NJ: Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 130:663–679. 2011. View Article : Google Scholar : PubMed/NCBI
10	Janssen EA, Slewa A, Gudlaugsson E, et al: Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol. 23:1567–1576. 2010. View Article : Google Scholar : PubMed/NCBI
11	de Rinaldis E, Gazinska P, Mera A, et al: Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics. 14:6432013. View Article : Google Scholar : PubMed/NCBI
12	Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, et al: Triple-negative and luminal breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol. 35:7733–7741. 2014. View Article : Google Scholar : PubMed/NCBI
13	Farazi TA, Ten Hoeve JJ, Brown M, et al: Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol. 15:R92014. View Article : Google Scholar : PubMed/NCBI
14	Nassirpour R, Mehta PP, Baxi SM and Yin MJ: miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One. 8:e621702013. View Article : Google Scholar : PubMed/NCBI
15	Sharma SB, Lin CC, Farrugia MK, et al: microRNAs-206 and -21 cooperate to promote RAS-ERK signaling by suppressing the translation of RASA1 and SPRED1. Mol Cell Biol. 34:4143–4164. 2014. View Article : Google Scholar : PubMed/NCBI
16	Dong G, Liang X, Wang D, et al: High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 31:572014. View Article : Google Scholar : PubMed/NCBI
17	Wang C, Zheng X, Shen C and Shi Y: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
18	Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D and Schiemann WP: TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 123:150–163. 2013. View Article : Google Scholar :
19	Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
20	Howe EN, Cochrane DR and Richer JK: Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 13:R452011. View Article : Google Scholar : PubMed/NCBI
21	Cascione L, Gasparini P, Lovat F, et al: Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 8:e559102013. View Article : Google Scholar : PubMed/NCBI
22	Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF and Scott RJ: Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer. 14:512014. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Tsouko E, Jonsson P, et al: miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer. Mol Oncol. 8:1690–1702. 2014. View Article : Google Scholar : PubMed/NCBI
24	Eades G, Wolfson B, Zhang Y, Li Q, Yao Y and Zhou Q: lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. Sep 24–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
25	Humphries B, Wang Z, Oom AL, et al: MicroRNA-200b targets protein kinase Calpha and suppresses triple-negative breast cancer metastasis. Carcinogenesis. 35:2254–2263. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lee ST, Feng M, Wei Y, et al: Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis. Proc Natl Acad Sci USA. 110:11121–11126. 2013. View Article : Google Scholar : PubMed/NCBI
27	Jin L, Lim M, Zhao S, et al: The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster. Breast Cancer Res Treat. 146:41–50. 2014. View Article : Google Scholar : PubMed/NCBI
28	Liu H, Wang Y, Li X, et al: Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1. Tumour Biol. 34:1713–1722. 2013. View Article : Google Scholar : PubMed/NCBI
29	Toyama T, Kondo N, Endo Y, et al: High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 42:256–263. 2012. View Article : Google Scholar : PubMed/NCBI
30	Kong W, He L, Richards EJ, et al: Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 33:679–689. 2014. View Article : Google Scholar :
31	Shen S, Sun Q, Liang Z, et al: A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One. 9:e1006642014. View Article : Google Scholar : PubMed/NCBI
32	Svoboda M, Sana J, Redova M, et al: MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 7:312012. View Article : Google Scholar : PubMed/NCBI
33	Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI
34	Deng X, Cao M, Zhang J, et al: Hyaluronic acid-chitosan nanoparticles for co-delivery of miR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 35:4333–4344. 2014. View Article : Google Scholar : PubMed/NCBI
35	Tan X, Peng J, Fu Y, et al: miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple negative breast cancer. Breast Cancer Res. 16:4352014. View Article : Google Scholar
36	Bisso A, Faleschini M, Zampa F, et al: Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle. 12:1679–1687. 2013. View Article : Google Scholar : PubMed/NCBI
37	Polytarchou C, Iliopoulos D and Struhl K: An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci USA. 109:14470–14475. 2012. View Article : Google Scholar : PubMed/NCBI
38	Ahmad A, Sarkar SH, Bitar B, et al: Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anti-cancer activity against breast cancer cells. Mol Cancer Ther. 11:2193–2201. 2012. View Article : Google Scholar : PubMed/NCBI
39	Si L, Jiang F, Li Y, et al: Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells. Mol Carcinog. Apr 14–2014.(Epub ahead of print). View Article : Google Scholar
40	Johansson J, Berg T, Kurzejamska E, et al: MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 32:5614–5624. 2013. View Article : Google Scholar : PubMed/NCBI
41	Aceto N, Sausgruber N, Brinkhaus H, et al: Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 18:529–537. 2012. View Article : Google Scholar : PubMed/NCBI
42	Augoff K, McCue B, Plow EF and Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer. 11:52012. View Article : Google Scholar : PubMed/NCBI
43	Krishnan K, Steptoe AL, Martin HC, et al: miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA. 19:1767–1780. 2013. View Article : Google Scholar : PubMed/NCBI